Microbiota-targeted therapies in inflammation resolution.
FMT
Gut microbiome
Inflammation
Live biotherapeutic products
Mucosal immunity
Probiotics
Journal
Seminars in immunology
ISSN: 1096-3618
Titre abrégé: Semin Immunol
Pays: England
ID NLM: 9009458
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
12
11
2021
revised:
24
01
2022
accepted:
15
02
2022
pubmed:
20
3
2022
medline:
17
12
2022
entrez:
19
3
2022
Statut:
ppublish
Résumé
Gut microbiota has been shown to systemically shape the immunological landscape, modulate homeostasis and play a role in both health and disease. Dysbiosis of gut microbiota promotes inflammation and contributes to the pathogenesis of several major disorders in gastrointestinal tract, metabolic, neurological and respiratory diseases. Much effort is now focused on understanding host-microbes interactions and new microbiota-targeted therapies are deeply investigated as a means to restore health or prevent disease. This review details the immunoregulatory role of the gut microbiota in health and disease and discusses the most recent strategies in manipulating individual patient's microbiota for the management and prevention of inflammatory conditions.
Identifiants
pubmed: 35304068
pii: S1044-5323(22)00016-1
doi: 10.1016/j.smim.2022.101599
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101599Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.